Primary Packaging for Small Pharma: A Survival Guide to Container Selection

Introduction

For small pharmaceutical companies and emerging biotech developers, container closure selection often sits far down the priority list, behind API formulation, clinical trial design, and investor relations. Yet packaging decisions made early—or, more frequently, delayed—can determine whether a drug reaches commercialization on schedule or becomes trapped in a cycle of regulatory deficiencies and costly line rejections. This article addresses the specific pain points that small pharma developers face when selecting primary packaging for injectable drug products, and offers practical strategies for navigating them.

The Resource Gap: Why Small Pharma Struggles with Packaging

Large pharmaceutical companies maintain dedicated packaging engineering teams, established supplier relationships, and decades of institutional knowledge about container selection. Small pharma companies and emerging biotechs rarely have these resources. With limited in-house capabilities primarily focused on drug research and development, these organizations typically need external support with container selection and early evaluation of drug-container interaction .

This gap has consequences. Packaging development may be deprioritized until Phase II or III, or deferred entirely to an outsourcing partner such as a CDMO . By the time packaging decisions become urgent, the window for optimizing container selection without disrupting development timelines has often closed.

Pain Point 1: The Regulatory Complexity of Extractables and Leachables

Extractables and leachables (E&L) assessment represents one of the most persistent regulatory hurdles for small pharma. In ANDA submissions, missing or inadequate E&L safety assessment is a recurring cause of major deficiencies and Complete Response Letters. FDA data from fiscal year 2023 shows that drug product deficiencies—including insufficient E/L method validation, incomplete E/L assessment, or lack of toxicological evaluation data to qualify identified leachables—account for a significant portion of quality-related major deficiencies .

For small companies without in-house toxicology expertise, the E&L requirements can feel like a moving target. The challenge is compounded by the fact that acceptable exposure thresholds and the scope of required testing vary depending on the drug product’s route of administration, dosing regimen, and patient population. Manufacturers of ANDAs frequently face deficiencies related to insufficient data for leachable testing, inadequate method validation, and unclear requirements for acceptable exposure levels .

The practical solution is not to avoid E&L assessment but to plan for it early. Early container selection, conducted during preclinical or Phase I, allows E&L studies to be integrated into the development timeline rather than treated as a late-stage regulatory checkbox . Container suppliers that provide pre-existing E&L data packages for their standard product lines can substantially reduce the testing burden on small pharma developers.

Pain Point 2: Small Batches, Big Packaging Problems

The shift toward personalized medicines, rare disease therapies, and smaller patient populations has driven adoption of smaller batch sizes and more frequent changeovers on fill-finish lines . This trend creates a particular challenge for small pharma: the packaging solutions designed for high-volume commercial production are often ill-suited for clinical-scale or small-batch commercial manufacturing.

The problems manifest in concrete ways. Consider a case study from freeze-drying scale-up: a product transferred from laboratory to commercial dryers encountered significant vial fogging at commercial scale, traced to the thermal treatment (depyrogenation) of vials . In another case, 100% vial breakage occurred during stoppering because the vials used at the commercial site were wider than those used previously—fewer vials per shelf meant each vial experienced higher pressure, ultimately crushing the glass .

These are not exotic failures. They are common consequences of using packaging components selected for laboratory convenience rather than evaluated for commercial-scale compatibility. For small pharma, the lesson is that container selection must account for the actual filling equipment, stoppering pressure, and thermal conditions that will be encountered at the intended manufacturing scale.

Pain Point 3: The Hidden Cost of “Good Enough” Glass

Not all Type I borosilicate glass performs identically. Differences in glass composition—particularly boron and aluminum content—melting practices, and surface treatment can produce measurable differences in chemical durability and delamination resistance. USP <660> has undergone its most significant revision in over a decade, moving from a composition-based classification to a performance-based framework, and formally recognizing new glass types including aluminosilicate and quartz .

For small pharma, this creates both risk and opportunity. The risk is that a supplier offering “Type I glass” at an attractive price may be providing glass whose surface hydrolytic resistance is marginal or inconsistent. The opportunity is that the expanded glass landscape now includes performance-equivalent options that may offer advantages for specific drug formulations.

Practical mitigation requires supplier transparency. Small pharma developers should request batch-specific hydrolytic resistance data, not just a general certificate of compliance. For high-risk formulations—high pH, citrate or phosphate buffers, high ionic strength—accelerated stability studies with the intended container should be conducted early, not deferred to late-stage development.

Pain Point 4: The Ready-to-Use Premium

Ready-to-use (RTU) container systems—pre-washed, pre-sterilized vials, syringes, and cartridges nested in standardized tubs—have gained popularity in clinical and small to medium commercial settings . For small pharma, RTU formats offer clear advantages: elimination of capital-intensive washing and depyrogenation equipment, reduced contamination risk from glass-to-glass contact, and simplified fill-finish workflows.

The trade-off is cost and flexibility. RTU containers carry a premium, and the standardized tub formats (typically 3-inch) may not accommodate every filling line or batch size. For companies with limited manufacturing capacity, however, the alternative—investing in validated washing and sterilization processes—often proves more expensive in both capital and time. RTU vials are projected to witness a higher compound annual growth rate over the forecast period, driven by their ability to eliminate the need for capital-intensive washing and sterilization processes and accelerate time-to-market for critical therapies .

Conclusion

Primary packaging selection is not a commodity decision. For small pharma companies, the consequences of getting it wrong—delayed approvals, failed batches, patient safety risks—far outweigh any upfront savings from a cheaper container. The available evidence points to a consistent conclusion: packaging development must begin early, container selection must be based on drug product requirements and manufacturing reality, and supplier relationships must be built on transparency and data sharing rather than price alone.

---